Corporate Vice President, Novo Nordisk. 18 year tenure in the Research and Development organisation at Novo Nordisk responsible for therapeutic areas including diabetes, devices, growth hormone deficiency, obesity and immunology. Experience from early stage drug development to post-approval life-cycle management.
Resedarch and Developement, infectious